CJJ300（Cat No.:I043831）is a potent and selective inhibitor of the enzyme protein kinase C (PKC), specifically targeting the PKC-θ isoform. PKC-θ plays a key role in T-cell activation and immune responses, making CJJ300 a promising candidate for modulating immune function. By inhibiting PKC-θ, CJJ300 can suppress T-cell-mediated inflammation and may be beneficial in treating autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Additionally, its potential to modulate immune responses offers possibilities for controlling T-cell-driven diseases and enhancing immune tolerance in certain therapeutic contexts.